Biotech News
Related news
BCDABioCardia2026-11-06 13:30 EST
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
BCDABioCardia2026-09-23 13:15 EST
BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission
BioCardia
Cardiovascular Cell Therapy Company BioCardia develops cellular and cell-derived therapies for cardiovascular and pulmonary diseases. Its platform includes autologous CardiAMP and allogeneic CardiALLO cell therapies, supported by the Helix delivery and Morph vascular-navigation technologies. CardiAMP Heart Failure Program CardiAMP Cell...
Recent company news
BCDABioCardia2026-11-12 21:19 EST
BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
BCDABioCardia2026-11-09 21:18 EST
BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
BCDABioCardia2026-11-06 13:30 EST
バイオカーディア、カーディAMP細胞治療システムに関して日本のPMDAとの臨床相談手続を完了し、販売承認申請の提出に向けて進捗
BCDABioCardia2026-11-06 13:30 EST
BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
BCDABioCardia2026-10-19 13:15 EST
BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
Stock data
- Close
- 0.77 USD
- Market cap
- 10.24M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
